Delcath Systems, Inc. (DCTH)

Delcath Systems' stock has experienced several events in the past six months, including a stock price decline of 16.15% in the week leading up to October 28, 2025, and by 7.00% over the last month. Over the past year, the stock has shown an 8.99% decrease. Despite a 29% share price plunge in July 2025, the stock had still gained 41% over the preceding year. Analyst ratings for DCTH have generally been positive, with several firms reiterating "Buy" or "Strong Buy" ratings and setting price targets ranging from $20.00 to $30.00. However, Wall Street Zen downgraded the stock from "buy" to "hold" in October 2025. The company reported strong financial results for the second quarter of 2025, with revenue of $24.2 million, exceeding estimates and representing a 211% year-over-year growth. Net income for Q2 2025 was $2.7 million, a significant improvement from a net loss in the prior year. Delcath Systems also announced preliminary third-quarter 2025 financial results and is scheduled to host an earnings call on November 4, 2025. News of the investigator-initiated CHOPIN clinical trial meeting its primary endpoint was also released in October 2025.

Information explicitly detailing demand seasonality for Delcath Systems' products and services is not publicly available in the provided search results. The company has reported significant revenue growth, but there is no indication of seasonal fluctuations in demand for its specialized liver cancer treatments.

Delcath Systems, Inc. is an interventional oncology company focused on developing and commercializing innovative therapies for primary and metastatic liver cancers, operating within the Healthcare sector, specifically in the Drug Delivery Devices and Medical Specialties industries. The company's primary focus is on delivering high-dose chemotherapy directly to the liver while minimizing systemic exposure and associated side effects. Its major products include the HEPZATO KIT™ and the CHEMOSAT® Hepatic Delivery System for Melphalan. The HEPZATO KIT is approved in the United States for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. In Europe, the device-only configuration of the Hepatic Delivery System (HDS) is approved for sale under the trade name CHEMOSAT.

Delcath Systems, Inc. operates in the United States and Europe, with its headquarters located in Queensbury, New York, USA.

Delcath Systems generally maintains a positive brand reputation within the financial and medical communities, largely driven by its innovative oncology treatments and ongoing clinical advancements. The company has received a "Moderate Buy" or "Strong Buy" consensus rating from analysts. The investigator-initiated CHOPIN clinical trial met its primary endpoint, with results presented at the ESMO conference in October 2025, showing that combining Delcath's liver-targeted chemo (HEPZATO) with immunotherapy helped a significant percentage of patients stay cancer-free for a year. Delcath Systems announced a new clinical study in March 2025 to evaluate the efficacy and safety of liver-directed therapy for patients with metastatic breast cancer with liver-dominant disease. The company also dosed its first patient in a Phase 2 clinical trial of HEPZATO in liver-dominant metastatic colorectal cancer in August 2025. The company reported robust revenue growth of 211% year-over-year in Q2 2025 and achieved positive adjusted EBITDA and cash flow. No specific negative events significantly impacting Delcath Systems' brand reputation in the past year were found in the search results.

Delcath Systems (DCTH) is owned by a mix of institutional shareholders, insiders, and retail investors. Institutional shareholders hold approximately 52.44% to 61.12% of the company's stock. Insiders own around 31.14% to 69.51% of the shares, while retail investors hold approximately 0.00% to 30.74%. Major institutional owners include Rosalind Advisors, Inc., BlackRock, Inc., Vanguard Group Inc, Deerfield Management Company, L.p., Citadel Advisors Llc, Geode Capital Management, Llc, IWM - iShares Russell 2000 ETF, Vivo Capital, LLC, and Marshall Wace, Llp. Rosalind Advisors Inc. is also noted as the largest individual Delcath Systems shareholder, owning 9.19 million shares, representing 26.27% of the company. Other significant individual owners include Steven A. J. Salamon and Gil Aharon. CEO Gerard Michel directly holds 0.9% of the total shares outstanding.